Dogwood Therapeutics Inc. held its annual meeting of stockholders on June 18, 2025. During the meeting, several proposals were voted on. The election of seven nominees to serve as directors of the company was approved. The appointment of Forvis Mazars, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. Additionally, an amendment to the Dogwood Therapeutics, Inc. Amended and Restated 2020 Equity Incentive Plan, increasing the number of shares reserved for issuance, was approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.